Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

October 1, 2024

FDA grants approval for Fresenius-Formycon’s biosimilar Otulfi

The US Food and Drug Administration (FDA) has granted approval for Fresenius Kabi and Formycon’s Otulfi (ustekinumab-aauz), a ustekinumab biosimilar to the reference medicine Stelara (ustekinumab).

FDA grants approval for Fresenius-Formycon’s biosimilar Otulfi